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Abstract 
Sub-endometrial junctional zone peristalsis is increased by ovarian stimulation and traumatic 
embryo transfer, and is linked with decreased implantation and pregnancy rates in assisted 
reproduction treatments. Various agents have been used to inhibit uterine hyper-peristalsis at 
the time of embryo transfer with conflicting results. This systematic review aimed to identify 
if uterine relaxants administered in the peri-implantation period during assisted reproduction 
treatments could improve pregnancy outcomes through literature search with no language 
restrictions. The review reports on 3546 patients in 17 randomized controlled trials published 
between 1993 and 2014. Women undergoing assisted reproduction techniques who either 
received a uterine relaxant agent in the peri-implantation period versus placebo or no 
treatment were included. Primary outcome was live birth rate. The meta-analyses did not 
show statistically significant benefit of any uterine relaxing agents on live birth rate. Other 
meta-analyses did not show a significant effect on the clinical pregnancy, spontaneous 
abortion, ectopic pregnancy and multiple pregnancy rate. Most of the included studies were 
of low quality and lacked significant power to detect minimally important effect. Evidence is 
insufficient to recommend using these agents in routine practice. Further methodologically 
robust randomized controlled trials with more refined selection criteria might reveal a 
beneficial effect. 
 
KEYWORDS: Embryo transfer, assisted reproduction, oxytocin antagonists, prostaglandin 
synthetase inhibitors, uterine contractions 
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<A>Introduction 
Successful embryo implantation in assisted reproduction technique cycles depends on embryo 
quality, endometrial receptivity and a non-traumatic embryo transfer.  Difficult and traumatic 
embryo transfer has been strongly linked to lower pregnancy rates (Kovacs, 1999, 
Schoolcraft et al., 2001).  It has been shown that difficult embryo transfer stimulates uterine 
junctional zone contractions (Lesny et al., 1998).  This has been postulated to lead to non-
adherence of the embryo(s) to the endometrium, expulsion of the embryos from the uterine 
cavity shortly after embryo transfer (Lesny et al., 1998; Mansour et al., 1990; Lesny and 
Killick, 2004), or both.  Furthermore, it has also been shown in normal fertile women that 
sub-endometrial peristalsis of the junctional zone myometrium progressively increases during 
menstrual cycle reaching a peak at time of ovulation with the pattern changing from 
predominantly ante-grade (fundo-cervical) in the menstrual and proliferative phase to 
retrograde (cervico-fundal) or opposing contractions in the early luteal phase (Lyons et al., 
1991; van Gestel et al., 2003). The frequency of sub-endometrial peristalsis has been shown 
to be higher in ovarian stimulation cycles compared with natural cycles but generally follows 
the same pattern as in natural cycles (Lesny et al., 1998; Zhu et al., 2012). Fanchin et al., 
showed that the pregnancy and implantation rates correlate negatively with the frequency of 
these contractions. Clinical , ongoing pregnancy and implantation rates decrease significantly  
in a stepwise  manner with increasing frequency of uterine contractions at time of embryo 
transfer (Fanchin et al., 1998). The same findings has been reported in a small study in 
natural cycles (Jland et al., 1997).  These findings from previous studies suggest that women 
with a background increase in the sub-endometrial peristalsis may have further increase in the 
frequency of contractions if embryo transfer is traumatic, decreasing the implantation 
potential.  To decrease this detrimental impact of sub-endometrial hyper-peristalsis it is 
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imperative to exercise utmost care by performing gentle atraumatic embryo transfer aiming to 
minimize trauma to the endometrium and  avoid touching the uterine fundus.  
The practitioner’s ability to perform atraumatic embryo transfer and other patient-related 
factors such as endometriosis (Bulletti et al., 2002) or the presence of fibroids (Yoshino et 
al., 2010) may also affect uterine contractions. It has, therefore, been suggested that using 
pharmacological agents that inhibit uterine contractions around the time of embryo transfer 
may lead to an improvement in implantation and pregnancy rates.  The potential candidate  
agents to exert this effect include: oxytocin receptor antagonists (ORA); these drugs act by 
antagonising naturally circulating and locally synthesized oxytocin as well as vasopressin at 
their receptors in the myometrium  promoting uterine relaxation (Pierzynski, 2011);  
prostaglandin synthetase (cyclooxygenase) inhibitors (PGSI); these drugs act by reducing 
levels of various prostaglandins such as PGF2 alpha, PGE2 and thromboxane A2, which are 
implicated in the induction of myometrial contractions in non-pregnant and pregnant uteri 
(Hagenfeldt, 1987; Olson et al., 2003; Marjoribanks et al., 2010); nitric oxide donors; these 
drugs are potent smooth muscle relaxants which act by increasing levels of nitric oxide and 
nitrites in the myometrium. This helps with vasodilatation and may help by inducing 
relaxation of the smooth muscles of the myometrium as shown in pregnancy (Lees et al., 
1999; Bisits et al., 2004); beta-adrenergic receptor agonists; these drugs act by stimulating 
beta-adrenergic receptors  in the myometrium, promoting the relaxation of the smooth muscle 
in cases of preterm labour (Leveno et al., 1986) and in the non-pregnant uterus (Fedorowicz 
et al., 2012); anti-cholinergic agents; these drugs act by antagonising the effect of 
acetylcholine at the muscarinic receptor promoting relaxation of the myometrial smooth 
muscles (Nakai et al., 2008; Kido et al., 2009); and calcium channel blockers; these drugs 
inhibit the influx of calcium ions through the cell membranes of smooth muscle, inhibiting 
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contractions. They have been used for tocolysis (Flenady et al., 2014) and treatment of 
dysmenorrhoea (Childress and Katz, 1994). 
 
Many randomized controlled trials (RCTs) have been conducted to evaluate the efficacy of 
these drugs when administered in the peri-implantation period of assisted reproduction 
technique cycles (Shaker et al., 1993; Tsirigotis et al., 2000; Ohl et al., 2002; Pinheiro et al., 
2003; Farzi, 2005; Bernabeu et al., 2006; Firouzabadi RD, 2007; Dal Prato and Borini, 2009; 
Moraloglu et al., 2010; Hanevik et al., 2012; Zargar,  2013; Ng et al., 2014).  The results of 
these trials, however, have been conflicting. Consequently, their use in routine clinical 
practice within assisted reproduction treatment is not recommended.  The aim of our study 
was to conduct a  systematic review to identify all relevant RCTs and summarize the effect of 
these drugs on live birth  and clinical pregnancy rates after assisted reproduction technique 
cycles as well as the safety of these medications.  
 
<A>Materials and methods 
The population of interest for our review were women undergoing assisted reproduction 
treatment cycles. The intervention of interest was administration of uterine relaxant drugs 
during the peri-implantation period of the assisted reproduction technique cycle.  The peri-
implantation period was defined as the period spanning from the day of oocyte retrieval until 
3 days after embryo transfer in assisted reproduction technique cycles in humans, as this is 
the period when early events of the implantation process take place.  The comparator 
intervention was placebo, no treatment or an alternative type of uterine relaxant drug. The 
primary outcome of interest was live birth rate.  Secondary outcomes were clinical pregnancy 
rate, biochemical pregnancy rates,  spontaneous abortion rates (including both biochemical 
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pregnancy losses and clinical spontaneous abortions), ectopic pregnancy rates and multiple 
pregnancy rates. We also sought to identify any reports of side-effects or serious reactions to 
the agents used in the included trials to assess any potential harm. 
<B>Eligibility criteria 
Studies were included if they were RCTs reporting on the use of any of the uterine relaxing 
agents in the peri-implantation period. Case reports, observational cohort studies, 
retrospective studies and non-randomized trials were excluded.  Studies reporting only on 
surrogate outcomes (i.e. frequency of uterine contractions or patient discomfort) without 
reports on clinically relevant outcomes (i.e. clinical pregnancy rate, on-going pregnancy rate 
or live birth rate) were also excluded. 
<B>Search and study selection 
A literature search of multiple databases; MEDLINE (1978–2014), Embase (1978–2014), 
Cochrane Register of Controlled Trials (CENTRAL)  (1978–014), ISI conference proceedings 
(1978–2014) and the controlled trials registers was conducted. Searches of the reference lists 
of the retrieved citations were conducted and contact made with the primary authors for other 
potentially relevant studies and to collect more information on the included studies.  When 
only abstracts were available, the primary authors were also contacted for more information 
for analysis when feasible.  No language restrictions were applied. 
The search strategy (Supplementary Table 1) involved use of the MeSH and text words to 
form three groups of studies to retrieve RCTS reporting on uterine relaxants in assisted 
reproduction technique cycles using the following: (reproductive assisted techniques), 
(fertilization in vitro), (intracytoplasmic sperm injection) combined with Boolean operator 
(OR)  and ‘Randomised controlled trials’ and ‘controlled studies’ combined with (OR) and  
Page 6 of 44
7 
 
the various pharmacological agents/classes included in the review combined with (OR).  The 
three groups of studies were combined together with the Boolean operator AND.  
Two independent reviewers (MK and RD) selected the studies. The titles and abstracts were 
scrutinized, and the decision for inclusion or exclusion was made according to the predefined 
inclusion criteria. The two reviewers were not blinded to the full manuscript data. Any 
disagreements between the two reviewers were resolved by arbitration by a third reviewer 
(AC).  The full manuscripts of the titles and abstracts that were considered to be relevant for 
inclusion were then obtained.  In the case of duplicate publication, then the most recent and 
complete versions were selected. The full manuscripts were then examined and data were 
extracted by the same two independent reviewers. 
<B>Validity assessment 
Two reviewers (MK and RD) assessed the included manuscripts for validity using the quality 
criteria recommended by Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins, 2011). These included method and adequacy of randomization, achievement of 
allocation concealment (to assess selection bias), blinding of participants (to assess for 
performance bias) and assessors of outcomes (to assess for detection bias) and adequacy of 
follow-up (to assess for attrition bias) and reporting of all relevant outcomes (to assess for 
reporting bias). Assessment for publication bias in the included studies for the outcome of 
clinical pregnancy was made using assessment for the symmetry of the funnel Plot 
(Supplementary Figure 1) and Egger’s test, and with the Bias statistic  for the  test 1.12 
95% CI –0.7 to 2.96; P = 0.2 (Egger et al., 1997). Another assessment of publication bias for 
effect of small studies using Harbord modification of Egger’s test showed bias statistic of 1.1 
and 95% CI of –0.67 to 2.87 (Harbord et al., 2006)  Both tests and the symmetry of the 
funnel plot indicating no evidence of publication bias. The same methodology for detecting 
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publication bias could not be carried out owing to the small number of studies reporting on 
live birth.  
Meta-analysis of the results of the reported outcomes was carried out using Review Manager 
(RevMan version 5.3 for Windows) software from the Cochrane collaboration. Summary of 
effect size was presented using relative risk and random effects model. Assessment for 
statistical heterogeneity was made using I
2
,
 
with a value above 50% indicating substantial 
heterogeneity. The PRISMA group guideline for reporting of systematic reviews (Moher et 
al., 2009) was used for compiling this systematic review. 
It was decided a priori that, as the agents included in this review belong to different classes 
of pharmacological agents, it would not be appropriate to reach a practice recommendation 
from pooling findings of all the included studies in a single meta-analysis. Therefore, 
separate meta-analyses were conducted where feasible for each class of drugs.   
To conclude and recommend from the appraised evidence, The Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Working Group methodology for 
assessment of the strength of treatment effect and quality of evidence was used for all uterine 
relaxing agents and for individual groups of medications. This was done with the use of 
GRADE pro software available online from the GRADE working group (Guyatt et al., 2008). 
<A>Results 
The literature search yielded a total of 2000 potentially relevant citations. After screening of  
titles and abstracts, and removal of duplicates, 1931 citations were excluded, as they clearly 
did not meet the inclusion criteria, and the full texts for 69 citations were assessed. Of these 
69 articles, 52 were excluded as they did not satisfy our inclusion criteria (Figure 1).  Of 
these 52 studies, four were non-relevant RCTs and three were RCTs reporting only on uterine 
contractions, 23 were prospective observational cohort studies, eight were retrospective 
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cohort studies, four were case reports, four were narrative reviews, three were animal studies, 
two were systematic reviews that were not relevant and one was a relevant systematic review 
but only available as poster presentation for use of oxytocin antagonists.   
Seventeen studies were eligible for inclusion in our review. These studies included 3546 
patients. The characteristics of the 17 included studies are presented in Table 1.  The 
publication dates  of the 17 studies that were included ranged between 1993 and 2014.  
Sample sizes varied from 27 to 800 participants. Two studies investigated the use of oxytocin 
receptor antagonists  (atosiban) in the peri-implantation period (Moraloglu et al., 2010; Ng et 
al., 2014). Four studies investigated the use of beta adrenergic receptors agonists (Tsirigottis 
et al., 2000; Pinheiro et al., 2003; Rabiee et al., 2011; Hanevik et al., 2012).  Seven studies 
investigated the use of prostaglandin synthetase inhibitors (Moon et al., 2004; Bernabeu et 
al., 2006; Asgharnia et al., 2007;  Firouzabadi et al., 2007; Dal Prato et al., 2009;  
Sohrabvand et al., 2009; Sohrabvand, 2014).  Three studies reported the findings of trials 
investigating the use of the nitric oxide donor in the form of nitroglycerin patch (Shaker et 
al., 1993; Ohl et al., 2002; Farzi et al., 2005) and two studies investigated the use of the 
antimuscarinic agent Hyoscine (Sohrabvand et al., 2009; Zargar, 2013).  
The search did not yield any relevant studies reporting on the use of calcium channel 
blockers; however, a registered trial for the use of nifedipine in the peri-implantation period 
in frozen embryo transfer cycles was identified.  This study has not yet started recruiting 
(Meir, 2014). 
The results of the Cochrane quality assessment for the included trials are presented in Table 
2, Figure 2 and Supplementary Tables  2–5.  The quality of the included studies was 
generally low.  The methods for randomization were unclear or inadequate in 11 out of the 17 
included trials.  Allocation concealment was inadequate or unclear in 13 trials. Participant 
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blinding was lacking or unclear in nine trials. Assessor blinding was lacking or inadequately 
described in  13 trials.  In four of the 17 studies, follow-up was incomplete or a large number 
of participants dropped out after recruitment, and reporting of clinically relevant outcomes 
was incomplete in 15 out of the 17 trials.   
 
<B>Live birth rate 
Only four studies (totalling 1317 patients) reported on the outcome of live birth. One study 
compared oxytocin receptor antagonist atosiban with no treatment (Ng et al., 2014). This 
study did not show any statistically significant effect on live birth rate, with relative risk of 
1.05 (95% CI 0.87 to 1.25). One study (Hanevik et al., 2012) compared beta adrenergic 
receptor agonist versus no treatment.  This study found  no significant effect  with a relative 
risk  of 0.85 (95% CI 0.60 to 1.20) for live birth.  Two studies compared nitric oxide donor 
with no treatment (Ohl et al., 2002; Farzi et al., 2005), and showed a relative risk of 1.11 
(95% CI 0.68 to 1.80) for live birth showing a non-significant effect (Figure 3).  
 
<B>Clinical pregnancy rate 
Thirteen studies reported on the outcome of clinical pregnancy rate with a total sample size of 
2760 patients. Only one study reporting on the use of the anticholinergic agent Hyoscine 
(Zargar et al., 2013) showed a significant beneficial effect. This study gave a relative risk of 
2.33 (95% CI 1.15 to 4.74). This was the only study reporting on clinical pregnancy outcome 
after the use of anticholinergic drugs, and included only small number of patients. Two 
studies reported on the use of ORA (Moraloglu et al., 2010; Ng et al., 2014).  Meta-analysis 
of these two studies gave a pooled  relative risk of 1.26 (95% CI 0.85 to 1.87) with no 
detectable statistically significant effect (Figure 4). Four studies investigated the use of  
Comment [S1]: Author:  it is usual to use generic 
drug names. should the generic be used here 
(hyoscine butylbromide)? 
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PGSI (Moon et al., 2004; Bernabeu et al. 2006; Firouzabadi et al., 2007; Dal Prato et al. 
2009).  Pooling of these four studies gave a relative risk of 1.36 (95% CI 0.87 to 2.11), with 
no statistically significant effect.  Statistically significant heterogeneity was found in the two 
meta-analyses for oxytocin receptor antagonists (I
2 
= 73%; P = 0.05) prostaglandins 
synthetase inhibitors ( I
2  
= 77%; P = 0.004).  
Other classes of uterine relaxing agents also did not show statistically significant effect in 
clinical pregnancy rate compared with placebo. Three studies (Tsirigottis et al., 2000; 
Pinheiro et al., 2003; Hanevik et al., 2012) reported on effect of beta adrenergic receptor 
agonist on clinical pregnancy rate.  Pooling of the findings of these studies showed a relative 
risk  of 0.99 (95% CI 0.59 to 1.66) (Figure 4). Three studies (Shaker et al.,1993; Ohl et al., 
2002; Farzi et al., 2005) compared nitric oxide donors with no treatment with pooled  relative 
risk  of 0.97 (95% CI 0.70 to 1.36) of these results showing no significant effect on clinical 
pregnancy rate (Figure 4).   
Publication bias, as displayed by the symmetrical funnel plot as shown in (Supplementary 
Figure 1) and Egger test result above, was not evident. 
  
<B>Other secondary outcomes 
Ten studies reported on the outcome of biochemical pregnancy rate, with one study 
(Sohrabvand et al. 2009) reporting on more than one drug  (Supplementary Figure 3).  No 
significant effect was found on biochemical pregnancy rate for any of the groups of uterine 
relaxants with RR 1.10 (95% CI 0.96 to 1.25),  0.93 ( 95% CI 0.69 to 1.26), 0.88 (95% CI 
0.34 to 2.23), 1.07 (95% CI 0.74 to 1.55) and 1.71 (95% CI 0.92 to 3.19) for the ORA (Ng et 
al., 2014), PGSI (Bernabeu et al., 2006; Firouzabadi et al., 2007; Dal Prato et al., 2009; 
Sohrabavand et al., 2009; Sohrabavand et al., 2014) beta-adrenergic receptor agonists 
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(Rabiee et al., 2011), nitric oxide donors (Ohl et al., 2002; Farzi et al., 2005) and 
antimuscarinic  agents (Sohrabavand et al., 2009; Zargar et al., 2013),  respectively.  
Nine studies reported on the spontaneous abortion rate (Supplementary Figure 4). The 
meta-analyses on spontaneous abortion rates showed no statistically significant  difference 
between the intervention and control groups in any of the uterine relaxants groups with RR 
0.95  (95% CI 0.64 to 1.40), 0.57 (95% CI 0.27 to 1.22), 0.60 (95% CI 0.15 to 2.42) and 0.89 
(95% CI 0.40 to 1.99) for ORA (Moraloglu et al. 2010; Ng et al., 2014), PGSI (Bernabeu et 
al., 2006; Firouzabadi et al., 2007; Dal Prato et al., 2009), B adrenergic receptor agonists 
(Pinheiro et al., 2003; Hanevik et al., 2012) and nitric oxide donors (Ohl et al., 2002; Farzi et 
al., 2005), respectively.  
Only three studies reported on the outcome of ectopic pregnancy; one study reporting on 
oxytocin antagonist (Ng et al., 2014), one on prostaglandin synthetase inhibitors (Dal Prato et 
al.,2009) and one study on  nitric oxide donors (Ohl et al., 2002). No statistically significant  
difference was found in the incidence of ectopic pregnancy in any of these individual studies 
between those that received uterine relaxing agents compared with no treatment with RR and 
95 % CI of 0.82 (0.34 to 1.98), 0.95 (0.06 to 14.13) and 0.56 (0.05 to 5.89) for the three 
studies, respectively. 
Five studies reported on the outcome of multiple pregnancy; two studies on the use of 
oxytocin receptor anatgonists (Moraloglu et al., 2010; Ng et al., 2014), two studies on  the 
use of prostaglandin synthetase inhibitors (Bernabeu et al., 2006; Firouzabadi et al., 2007) 
and one on the use of nitric oxide donors (Ohl et al., 2002)  (Supplementary Figure 5).  The 
pooled  RR and corresponding 95% CI were  0.86 (0.66 to 1.13) and 1.06 (0.57 to 1.97) for 
the ORA and PGSI respectively (Supplementary Figure 5). The RR and 95% CI for the 
study on nitric oxide donor was 0.95 (0.22 to 4.14).  
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No serious side-effects were reported in any of the trials included in the review (Table 1). 
The study by Ng et al., (2014), which used the oxytocin antagonist atosiban reported a higher 
rate of congenital abnormalities in the treatment group (3.2% compared with 1.6% in the 
placebo group). 
Using the GRADE approach for appraising the quality of included studies and effect size 
reported on the meta-analyses of various groups of uterine relaxants, we have shown that the 
current evidence for all groups showed non -significant effect based on very weak evidence  
(Table 3  and  Supplementary Tables  2–5) (Guyatt et al., 2008). 
 
<A>Discussion 
This systematic review sought to summarize  the current evidence for the use of different 
classes of uterine relaxants at the peri-implantation period in during assisted reproduction. 
Overall, the systematic review and meta-analyses shows that the identified evidence does not 
support the routine clinical use of these agents in assisted reproduction treatment cycles. 
Rigorous RCTs still need to be conducted, as the quality of the included studies was generally 
low with significant clinical and statistical heterogeneity in most meta-analyses. 
<B>Oxytocin receptor antagonists  
In the meta-analyses for the ORA, although there was a no statistically significant effect on 
live birth and clinical pregnancy rates, the number of patients included in the trials on ORA 
was 980 patients, which is underpowered to identify significant difference in live birth or 
clinical pregnancy rate at the set statistical significance limits. Thirty more clinical 
pregnancies occurred in the arm using oxytocin antagonist compared with placebo or no 
treatment. Although the 95% confidence interval for the clinical pregnancy outcome was not 
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statistically significant, the pooled point estimate of the risk ratios for clinical pregnancy rates 
was 1.26. 
The oxytocin receptor antagonist used in the trials in this review was atosiban, a mixed 
vasopressin and oxytocin antagonist and its use was limited to 2.5 h at the time of embryo 
transfer. Whether the use of a more selective oxytocin receptor antagonist such as barusiban, 
a longer duration of use in the peri-implantation period, or both, might show a greater 
beneficial effect remains to be seen.  The role of ORA in patients with recurrent implantation 
failure is still unclear. It has been shown in an observational study that ORA are beneficial in 
cases of recurrent implantation failure where cryopreserved embryos  were  transferred  in a 
hormonal replacement cycles (Lan et al., 2012). The trial by Ng et al. (2014) did not report a 
statistical increase in clinical pregnancy rate or live birth rate in patients with repeated cycles, 
although the authors cautioned against extrapolating this to patients with recurrent 
implantation failure. The result of an RCT registered in the Clinicaltrials.gov recruiting for 
the use of ORA in patients with repeated implantation failure is awaited (NCT01673399) 
(Decleer, 2015). 
The disadvantage of oxytocin receptor antagonists is the financial cost. It also requires 
intravenous infusion and carries the potential for serious side-effects. These include 
pulmonary oedema, which has been reported in obstetric populations using atosiban for 
tocolysis (Donders et al., 2008; Fernandez et al., 2011). In this review, no serious side-effects 
of atosiban or other classes of the drugs were reported.  
 
 
<B>Oral and transdermal uterine relaxants 
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The use of oral or transdermal agents is generally more appealing to patients and clinicians. 
In this review, the only oral agent that showed a significant effect on clinical pregnancy was 
the anticholinergic agent, hyoscine. This was, however, based on single clinical trial, which 
included a relatively small number of patients with low quality assessment grading and no 
reporting on  the primary outcome of live birth rate (Zargar, 2013). Another small trial 
showed improvement of biochemical pregnancy rate with hyoscine but no clear data on 
clinical pregnancy rate (Sohrabvand et al., 2009).  Therefore, caution must be taken when 
drawing any definitive conclusions for the use of these agents in routine clinical practice. 
No statistically significant effect was found on live birth or clinical pregnancy from meta-
analyses of other oral or transdermal agents. In the only RCT that exclusively included 
patients with recurrent implantation failure, however, a statistically significant effect was 
reported on clinical and ongoing pregnancy rate in the treatment arm using ritodrine 
(Tsirigotis et al., 2000). 
Interestingly we did not identify any studies that investigated the effectiveness of calcium 
channel blockers. A RCT has been egistered in clinicaltrials.gov (NCT02072291) that has not 
started recruiting yet and will investigate the use of nifedipine on uterine contractility and 
pregnancy rate in frozen embryo replacement cycle (Meir, 2014). The calcium channel 
blockers might  be a suitable alternative oral agent to ORA as the voltage and ligand gated 
calcium channels are more ubiquitous structures in the smooth muscle membranes of the 
myometrium (Sanborn, 2000) compared  with the oxytocin receptors, with ORA exerting 
their actions mainly through paracrine factors including prostaglandins rendering them 
functionally redundant especially in the non-pregnant uterus (Ivell et al., 2001)  
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Reassuringly, our review showed no increase in the incidence of adverse fertility outcomes.   
The relative risks for spontaneous abortion, ectopic pregnancy rate and multiple pregnancy 
rate were not significantly different between the treatment  and control groups. No major 
side-effects were reported from any of the agents studied in this review. Although a higher 
rate of congenital abnormalities was reported in the ORA treatment arm in one of the trials 
compared with placebo, the number reported was too small to allow conclusions to be drawn. 
Furthermore, the rate of congenital abnormalities reported was not markedly different from 
the generally expected congenital abnormalities in pregnant women, and the ORA was used 
for a short period before the actual implantation would have occurred, casting further doubt 
on a cause and effect relationship. 
<B>Strengths and weaknesses 
The strengths of this review mainly lie in its extensive and rigorous search strategy.  
Systematic searches were conducted on multiple healthcare literature databases without 
language restriction. There was also no evidence of publication bias. The main limitation of 
this review is the low quality of the included studies.  Most studies were of relatively small 
sample size to enable the authors to  detect a clinically important minimal difference in live 
birth rate and other important outcome. The included studies were also not statistically 
heterogeneous, which would limit the interpretation of our findings. The significant 
heterogeneity detected in these trials can be partially explained by different inclusion and 
exclusion criteria among included trials with differences in dose, duration and type of uterine 
relaxants used. Most of the trials had one or more of element of bias as shown in the quality 
assessment tables (Tables 2, 3 and Supplementary Tables 2–5). This tends to overestimate 
the treatment effect limiting confidence in the findings. This has been reflected in the very 
low grading of the quality of evidence from the included trials, as appraised using the 
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GRADE approach, owing to serious methodological shortfalls, e.g lack of allocation 
concealment or blinding. 
Subgroup analyses could not be carried out owing to lack of available data reporting 
exclusively on certain groups of patients, e.g recurrent implantation failure, endometriosis. 
Sensitivity analyses and meta-regression to adjust for effect of confounding variables was not 
deemed necessary, as most analyses did not show statistically significant effects. 
Another important weakness in the included studies was the general lack of power to detect 
minimally important difference in primary outcome even after pooling studies within groups, 
e.g. the predicted sample size required to detect a minimally significant effect of 5% 
improvement in live birth assuming a background rate of 35% will be nearly 2942 patients  
(1471 patients in each group) for a study with a power of 0.8 and statistical significance set at 
0.05. This sample size was not achieved in any of the included meta-analyses indicating 
possibility of false negative findings (Type II error). 
In conclusion, insufficient evidence is currently avaailble to support the use of uterine 
relaxant agents around the time of embryo transfer in routine clinical practice. Given the 
methodological short comings of the current evidence, however, larger robust RCTs are 
clearly needed to investigate the usefulness of these agents if any (in particular, 
anticholinergic agents, oxytocin receptor antagonists and calcium channel blockers). It is 
possible that careful patient selection for the use of these agents might show greater benefit in 
future RCTs, e.g. patients who reported pain after previous embryo transfer, those where 
difficult embryo transfer is anticipated or patients with adenomyosis/endometriosis. With 
better scanning techniques and equipment, uterine hyper-peristalsis might be more readily 
detectable. This would allow the improved identification of patients who might benefit from 
these agents.  
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Supplementary Figure legends 
Supplementary Figure 1: Funnel plot for studies reporting on clinical pregnancy rate after 
the use of uterine relaxants in the peri-implantation period. 
 
Supplementary Figure 2:  Quality parameters of the included studies. 
 
Supplementary Figure 3:  Forest plot of the risk ratios of biochemical pregnancy rate after 
use of uterine relaxants at the peri-implantation period. 
 
Supplementary Figure 4:  Forest plot of the risk ratios of spontaneous abortion rate after use 
of uterine relaxants at the peri-implantation period. 
 
Supplementary Figure 5:  Forest plot of the risk ratios  of multiple pregnancy rate after use 
of uterine relaxants at the peri-implantation period. 
 
 
Figure legends 
Figure 1: Selection process for included papers. RCT, randomized controlled trial. 
Figure 2: Quality assessment for sources of bias in the included studies.  
Figure 3:  Forest plot of the meta-analysis of risk ratio of the effect of uterine relaxants 
(nitric oxide donors) used in the peri-implantation period on the live birth rate. 
Figure 4:  Forest plot of the risk ratios of clinical pregnancy rate after use of uterine relaxants 
at the peri-implantation period. 
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Table 1.  Characteristics of the included studies. 
 
Study Participants Intervention Comparison 
(control) 
Outcomes Results  
(treatment versus 
control group) 
Asgharnia et 
al., 2007 
500 patients undergoing 
IVF–ICSI treatment 
because of male factor, 
tubal, anovulatory and 
unexplained factor infertility. 
Women with uterine 
pathology, such as fibroids 
or Asherman’s syndrome, 
were excluded. 
Intervention group (n = 250) 
received long protocol and 
ovarian stimulation with 
piroxicam 10 mg orally 1–2 
h before embryo transfer. 
Control group (n = 
250) received 
same long 
protocol and 
ovarian 
stimulation and 
placebo tablet 1–
2 h before embryo 
transfer.  
Clinical 
pregnancy rate 
NAa 
Bernabeu et 
al., 2006 
173 first cycle oocyte 
recipients following IVF–
ICSI with no allergies to 
non-steroidal anti-
inflammatory drugs and no 
history of neurological or 
gastrointestinal diseases. 
Women who had 
experienced recurrent 
spontaneous abortion or  
severe endometriosis and 
endometrial pathology were 
excluded. 
Egg donation treatment 
protocol using ethinyl 
oestradiol and vaginal 
micronized progesterone  
and Indomethacin 100 mg 
given as rectal 
suppositories every 12 h 
(three doses) starting on the 
night before embryo 
transfer. The non-
intervention group did not 
receive any placebo. 
 
Standard egg 
donation 
treatment for the 
control arm 
without placebo 
treatment. 
Biochemical 
pregnancy rate 
 
Clinical 
pregnancy rate 
 
Implantation rate 
 
 
Spontaneous 
abortion rate 
43/72 (59.7%) 
versus 40/64 
(62.5%) 
36/72 (50%) 
versus 32/64 
(50%) 
 
52/191 (27.2%) 
versus 44/168 
(26.2%) 
7/43 (16.2%) 
versus 8/40 (20%)  
13/36 ( 36.1%) 
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Multiple 
pregnancy rate 
versus11/32 
(34.4%) 
Dal Prato et 
al., 2009 
200 women younger than 
44 years at enrolment for 
IVF–ICSI cycles for male 
factor, tubal or 
endometriosis-related 
infertility with no more than 
two previous embryo 
transfers. Patients with 
inadequate ovarian reserve 
as indicated by high 
baseline FSH over15 IU/l or 
previous poor response or 
patients with more than two 
embryo transfers were 
excluded. 
Standard IVF–ICSI 
treatment with piroxicam 10 
mg orally 1–2 h before 
embryo transfer. 
Standard IVF–
ICSI treatment 
without placebo. 
Biochemical 
pregnancy rate 
Clinical 
pregnancy rate 
 
Implantation rate 
               
 
Spontaneous 
abortion rate       
 
 
Ectopic 
pregnancy rate 
37/100 (37%) 
versus 47/100 
(47%) 
34/100 (34%) 
versus 38/100 
(38%) 
48/250 (19.2%) 
versus 56/256 
(21.9%) 
 
7/37 (18.9) versus 
14/47 (29.8.%) 
 
1/34 (2.9%) versus 
2/38 (5.3%)                                          
Farzi et al., 
2005 
100 consecutive patients 
(cycles) undergoing IVF–
ICSI treatment in standard 
long protocol for pituitary 
down regulation and 
ovarian stimulation for 
various male, female and 
combined indications 
A single oral dose of 
nitrogylcerin (0.4 mg 15 min 
before embryo transfer). 
A single oral dose 
of placebo 15 min 
before embryo 
transfer. 
Biochemical 
pregnancy rate 
 
Clinical 
pregnancy rate 
 
19/50 (38%) 
versus 17/50 
(34%) 
 
16/50 (32%) 
versus 14/50 
(28%) 
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Patients with hypotension 
or hypertension or ASA 
grade greater than 1 or 
marked variation of supine 
and standing blood 
pressure were excluded. 
 
 
Live birth rate 
 
             
Spontaneous 
abortion rate 
 
 
13/50(26%) versus 
9/50 (18%) 
 
6/19 (31.6%) 
versus 8/17 (47%) 
Three biochemical 
pregnancy losses 
and tree clinical 
spontaneous 
abortions in the 
treatment group 
and three 
biochemical 
pregnancy  losses 
and five clinical 
spontaneous 
abortions in the 
control group  
Firouzabadi 
et al., 2007 
180 patients (cycles) 
undergoing IVF treatment 
for tubal, ovarian, male 
mixed and unexplained 
infertility all having standard 
long protocol of pituitary 
down regulation and 
ovarian stimulation.  
Single oral dose of 
piroxicam 10 mg 
administered to 90 patients 
(cycles) 1–2 h before 
embryo transfer. 
Placebo treatment 
administered 
orally to patients 
1–2 h before the 
embryo transfer. 
Implantation rate 
 
Biochemical 
pregnancy rate 
 
Clinical 
pregnancy rate 
Spontaneous 
12.3% versus 
7.7% 
 
24/90 (26.7)% 
versus 14/90 
(15.6%) 
 
23/90 (25.6%) 
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abortion rate        
 
 
Multiple 
pregnancy rate 
versus 9/90 
(10.0%) 
1/24 (4.2%) versus 
5/14 (35.7%) 
 
2/24 (8.3%) versus 
1/14 (7.1%) 
Hanevik et 
al., 2012 
279 patients younger than 
40 years with no abnormal 
uterine anatomy or 
azoospermia, who were 
non-diabetic with no 
hyperthyroidism and normal 
baseline FSH and normal 
quality embryos on day 2 
after oocyte retrieval 
Standard IVF–ICSI 
treatment with low-dose 
aspirin 75 mg/d from 
embryo transfer until 
pregnancy test and up to 9 
weeks gestation if patient is 
pregnant. Patients in the 
intervention group also 
received three doses of 
terbutaline 5 mg 3 h before 
embryo transfer, 6 h after 
embryo transfer and at 8 
am the morning after 
embryo transfer. 
Standard IVF–
ICSI without 
placebo 
treatment. 
Live birth rate 
 
Clinical 
pregnancy rate 
 
 
Spontaneous 
abortion rate 
 
 
 
Cancellation rate 
48/167 (28.7%) 
versus 38/112 
(33.9%) 
 
51/167 (30.5%) 
versus 47/112 
(42.0%) 
 
3/51(5.9%) versus  
9/47 (19.1%) 
 
14/167(8.4%) 
versus 6/112 
(5.4%) 
Moon et al., 
2004 
266 patients undergoing 
IVF–ICSI (188 fresh cycles 
and 78 frozen thawed 
embryo transfer) treatment 
Standard IVF–ICSI 
treatment with piroxicam 10 
mg orally 1–2 h before 
embryo transfer. 
Standard IVF–
ICSI fresh cycles 
or frozen thawed 
embryo transfer 
Implantation rate 
Clinical 
pregnancy rate 
18.7% versus 
8.6% 
54/133 (40.6%) 
versus 29/133 
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for male factor 
endometriosis, unexplained 
endometriosis and tubal 
factors infertility. No clear 
inclusion or exclusion 
criteria. 
protocol with 
placebo at the 
time of embryo 
transfer. 
(21.8%)   
Moraloglu et 
al., 2010 
180 patients having fresh 
IVF–ICSI treatment for 
male factor, tubal factor and 
unexplained infertility 
Patients were included if 
basal FSH was less than10 
IU/L, having first IVF cycle, 
long protocol and have at 
least two top quality 
embryos. 
 
Exclusion criteria were 
female age over 39 years, 
endocrine disorders (such 
as thyroid disorders and 
premature ovarian failure) 
severe male factor 
infertility, endometriosis, 
patients with more than 
three previous failed IVF 
cycles, frozen thawed 
embryo transfer, uterine 
anomalies, fibroids, 
hydrosalpinges and 
Standard IVF–ICSI 
treatment with long protocol 
and intravenous infusion of 
atosiban at a bolus dose of 
6.7 5mg 30 min before 
embryo transfer, continued 
at a rate of 18 mg/h then at 
a rate of 6mg/h for 2 h after 
embryo transfer (total 
administered dose 37.5 
mg). 
Standard IVF–
ICSI fresh cycles 
in long protocol 
with intravenous 
infusion of 
identical 
medicated bags 
with saline. 
Implantation rate   
 
 
Clinical 
pregnancy rate 
 
Spontaneous 
abortion rate 
 
 
 
Multiple 
pregnancy rate 
57/279 (20.4%) 
versus 34/270 
(12.6%) 
 
42/90 (46.7%) 
versus 26/90 
(28.9%)  
 
7/42 (16.7%) 
versus 6/26 
(23.1%) 
 
 
6/42 (14.3%) 
versus 5/26 
(19.2%)  
 
 
Page 30 of 44
31 
 
patients who have a history 
of difficult embryo transfer. 
Ng et al., 
2014 
800 patients having fresh 
IVF–ICSI treatment were 
recruited if they were 
younger than 43 years and 
had normal uterine cavity 
on ultrasound. 
Standard IVF–ICSI 
treatment and at fresh 
embryo transfer - 
intravenous infusion of 
atosiban at a bolus dose of 
6.75 mg 30 min before 
embryo transfer, continued 
at a rate of 18 mg/h then at 
a rate of 6 mg/h for 2 h after 
embryo transfer (total 
administered dose 37.5 mg) 
Standard IVF–
ICSI treatment 
and at fresh 
embryo transfer 
intravenous 
infusion of 
identically 
medicated bags 
with normal 
saline. 
Live birth rate 
 
 
Ongoing 
pregnancy rate 
 
 
 
Clinical 
pregnancy rate 
 
Biochemical 
pregnancy rate 
 
Spontaneous 
abortion rate 
 
Multiple 
pregnancy rate 
 
159/400 (39.8%) 
versus 152/400 
(38.0%) 
 
171/400 (42.8%) 
versus 
153/400(38.3%) 
 
 
201/400 (50.3%) 
versus 187/400 
(46.8%)   
217/400 (54.3%) 
versus 198/400 
(49.5%) 
 
37/217 (17.1%) 
versus 35/198 
(17.7%)  
65/217 (30.0%) 
versus 68/198 
(34.3%) 
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Ectopic 
pregnancy rate 
Side-effects 
Congenital 
abnormalities 
 
9/217 (4.1%) 
versus 10/198 
(5.1%) 
No serious 
adverse events 
4/125 (3.2%) 
versus 2/125 
(1.6%)* 
Ohl et al., 
2002 
138 patients with a history 
of at least two previous 
failed IVF–ICSI cycles 
despite transfer of two good 
quality embryos in each 
cycle. 
Patients were excluded if 
they did not have two good 
quality embryos to transfer 
during the trial or if they had 
a history of hypersensitivity 
to nitric oxide donors, heart 
failure, severe anaemia, 
high intracranial blood 
pressure or high intraocular 
pressure. 
IVF–ICSI treatment with 
long protocol and ovarian 
stimulation and 5 mg 
nitroglycerin patch applied 
once daily on the morning 
before embryo transfer and 
removed at bedtime. The 
nitroglycerin patch was then 
continued until either the 
results of pregnancy test 
was available or 
menstruation starts. 
IVF–ICSI 
treatment with 
long protocol and 
ovarian 
stimulation and 
placebo patch 
starting on the 
day before 
embryo transfer 
and continued till 
day of pregnancy 
test. Micronized 
progesterone 200 
mg intra-vaginally 
twice daily was 
used as luteal 
phase support in 
both intervention 
and control arms. 
Uterine artery 
pulsatility index 
on the day before 
and after embryo 
transfer 
Implantation rate 
 
Biochemical 
pregnancy rate 
 
Clinical 
pregnancy rate 
 
 
Live birth rate 
 
 
 
 
10.6% versus 
11.6% 
 
20/70 (28.6%) 
versus 
 
(19/68) (27.9%) 
 
 
15/70 (21.4%) 
versus 17/68 
(25%) 
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Spontaneous 
abortion rate 
 
 
Ectopic 
pregnancy 
rateMultiple 
pregnancy rate 
 
Side effects 
 
 
14/70 (20%) 
versus 
15/ 68 (22.1%) 
 
5/20 (25%) versus 
3/19 (15.8%) 
 
 
1/20 (5.0%) versus 
1/19 (5.3%) 
 
3/20 (15.0%) 
versus 3/19 
(15.6%) 
One patient in the 
placebo group had 
nervousness, inso-
mnia, constipation 
and feeling of 
weakness  
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Pinheiro et 
al., 2003 
225 patients undergoing 
ICSI treatment for male 
factor infertility.   
Long protocol for ovarian 
stimulation using fixed dose 
of 300 IU/day and two 
intervention arms: 
Group 1, n = 90 patients, 
taking terbutaline 10 mg 
orally daily for 15 days 
starting on the day of 
oocyte retrieval. 
Group 2, n =  90 patients 
taking ritodrine 20 mg orally 
daily for the same period as 
Group 1). 
 
Group 3, n = 45 
(control arm) 
received no 
treatment apart 
from the long 
protocol for 
ovarian 
stimulation and 
Uterogestan 800 
mg intravaginally 
daily until day of 
pregnancy test. 
Up to three 
embryos were 
transferred in all 
arms of the trial. 
Implantation rate 
 
 
Clinical 
Pregnancy rate 
 
 
Spontaneous 
abortion rate 
61/409 (14.9%) 
versus 19/126 
(15.1%) 
 
46/147 (31.3%) 
versus 13/45 
(28.9%)  
 
 
9/46 (19.6%) 
versus 2/13 
(15.3%) 
 
Rabiee et al., 
2011 
100 women aged 25–35 
years with infertility for over 
5 years undergoing IVF–
ICSI treatment for male 
factor, tubal factor, 
endometriosis or 
unexplained infertility. 
Patients were eligible for 
inclusion if they had a 
morphologically normal 
uterus. 
Exclusion criteria were any 
systemic illnesses.  
Intervention group (n = 50) 
received the same protocol 
in the control arm, as well 
as ritodrine 10 mg orally 
twice daily for 10 days 
starting from the day after 
oocyte retrieval. 
Control group (n = 
50) received long 
protocol of 
ovarian 
stimulation, Acetyl 
salicylic acid 80 
mg/d, 
erythromycin 400 
mg orally four 
times a day, 
heparin 5000 IU 
twice daily and 
progesterone 100 
mg IM and no 
placebo. 
Biochemical 
pregnancy rate 
Side-effect 
7/50(14.0%) 
versus 8/50 
(16.0%) 
One patient in the 
ritodrine group had 
headache and 
vertigo 
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Sohrabvand 
et al., 2014 
50 patients aged 20–35 
years undergoing IVF–ICSI 
treatment for tubal factor or 
ovulation disorder or severe 
male factor infertility with 
standard long protocol for 
pituitary down regulation 
and ovarian stimulation 
Exclusion criteria were 
patients with systemic 
diseases and endometriosis 
Single oral dose of 
Piroxicam 10 mg 30 min  
before embryo transfer with 
bed rest for 30 min after 
embryo transfer. 
No treatment 
before embryo 
transfer and bed 
rest for 30 min 
after embryo 
transfer. 
Biochemical 
pregnancy rate 
Abdominal 
cramps 
 
8/25 (32.0%)vs 
9/25 (36.0%) 
No patients in 
treatment groups 
had cramps and 
four patients in the 
control group had 
abdominal cramps 
Sohrabvand 
et al., 2009 
66 women recruited for 
three arms randomized 
controlled trial.  Patients 
were included if they had 
tubal factor, severe male 
factor or ovulatory infertility 
and they were having their 
first assisted reproduction 
treatment cycle.  
 
Exclusion criteria were 
patients with endometriosis 
and patients with systemic 
illnesses. 
 
Two interventions groups: 
Group A (n = 22) had in 
addition to long ovarian 
stimulation protocol, 
standard IVF–ICSI received 
10 mg rectal suppository of 
indomethacin 30 min before 
embryo transfer. 
Group B (n = 22) had the 
same protocol of ovarian 
stimulation and IVF, and 
received hyoscine 100 mg 
rectal suppository. 
Control group (n = 
22) received 
same protocol of 
ovarian 
stimulation and 
IVF–ICSI without 
any additional 
placebo 
treatment. 
Patients in all 
groups had a bed 
rest for 30 min 
after embryo 
transfer. 
Biochemical 
pregnancy rate  
 
 
 
 
Side-effects 
10/22 (45.5%) for 
hyoscine and  
3/22 (13.6%) for 
indomethacin  
versus  8/22 
(36.4%)  
 
No patients in the 
active treatment 
groups had side 
effects and three in 
the control group 
had abdominal 
cramps. 
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Tsirigotis et 
al., 2000 
27 Patients with three or 
more previous failed IVF 
attempts who also had 
lower abdominal pain after 
embryo transfer for few 
days or until pregnancy 
test. Patients had standard 
IVF and embryo transfer 
treatment in both treatment 
and control groups 
Intervention group received 
oral ritodrine 5 mg /6 h from 
the day of oocyte collection 
up to the day of pregnancy 
test. 
Control group did 
not receive any 
placebo 
Clinical 
pregnancy rate 
Ongoing 
pregnancy rate 
7/15(46.7%) 
versus 2/12 
(16.7%) 
5/15(33.3%) 
versus 0/12 (0%) 
Shaker et al., 
1993 
120 patients having IVF 
and embryo transfer were 
included.  
Intervention group had 
ovarian stimulation and IVF 
and received sublingual 
glyceryl trinitrate at the time 
of embryo transfer. 
Control group had 
the same protocol 
of ovarian 
stimulation and 
IVF and received 
a placebo 
sublingual tablet 
at the time of 
embryo transfer. 
Clinical 
pregnancy rate 
18/60 (30.0%) 
versus 19/60 
(31.7%) 
Zargar et al., 
2013 
142 patients aged 21–41 
years undergoing IVF–ICSI 
cycle for the treatment of 
male factor, tubal factor or 
ovulatory dysfunction and 
unexplained infertility. 
Patients had long protocol 
for pituitary down regulation 
and ovarian stimulation. 
An injection of hyoscine (25 
mg) 30 min before embryo 
transfer. 
No injections 
given to the 
control group. 
Biochemical 
pregnancy rates  
Clinical 
pregnancy rate 
 
 
21/71 (29.6%) 
versus 9/71 
(12.7%) 
21/71 (29.6%) 
versus 
9/71(12.7%) 
 
aNo numerical or percentage data available despite attempt of contacting the primary author. 
Page 36 of 44
37 
 
ASA, American Society of Anesthesiologists; ICSI, intracytoplasmic sperm injection. 
 
Table 2.  Quality assessment of the included studies. 
 
Study Randomization Allocation 
Concealment 
 
Blinding of 
participants 
Blinding 
of assessors 
Adequacy of 
reporting 
Selective reporting Other biases 
Asgharnia et al., 
2007 
Unclear method of 
Randomization. 
Unclear if 
allocation 
concealment 
was achieved. 
Placebo was 
used so 
blinding was 
likely 
achieved. 
Unclear if 
assessors were 
blinded to 
allocation  of 
patients. 
Unclear if all 
patients included 
are reported. 
Only statistical 
significance  
between 
pregnancy 
outcomes  
reported  and no 
data suitable for 
analysis on and 
no data on live 
birth and other 
important 
outcomes. 
Unclear if 
patients only 
allowed one 
cycle of 
treatment. 
Bernabeu et al., 
2006 
 
Adequate; 
random sequence 
numbers generated by 
epidemiologist. 
Inadequate.  
 
No; controls 
did not 
receive 
placebo. 
Unclear. 
 
Incomplete; 
around 21% of 
patients recruited 
were not reported 
on as they did not 
complete their 
treatment. 
Only clinical 
pregnancy and 
implantation rates 
and multiple 
pregnancies and 
spontaneous 
abortion rates;  
no data on live 
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birth or ectopic 
pregnancy rates 
or side-effects. 
Dal Prato et al., 
2009 
 
Adequate; 
independent 
statistician. 
Adequate.  
third party and 
using dark 
sealed 
envelopes. 
No; control 
arm did not 
receive 
placebo. 
Unclear. Adequate. 
 
Clinical 
pregnancy, 
implantation and 
spontaneous 
abortion rates 
reported; no 
reporting on live 
birth rates, 
multiple 
pregnancy rate or 
side-effects. 
Unclear if 
results are 
biased by 
protocol of 
study as only 
Three oocytes 
were 
inseminated 
in each 
patient. 
Farzi et al., 2005 Unclear method of 
randomization. 
Unclear Yes; by use 
of placebo 
Yes . Adequate 
reporting on all 
patients included 
in the study 
No reporting on 
ectopic 
pregnancy or 
multiple 
pregnancy rate or 
side-effects. 
 
Firouzabadi et al., 
2007 
Computer-generated 
random table. 
Adequate by a 
computer-
generated 
randomization 
and blinding of 
staff. 
Yes; by use 
of placebo. 
Yes. Adequate 
reporting of all 
patients included 
in the study. 
No reporting on 
live birth rate and 
ectopic 
pregnancy rate  
or side-effects of 
the drug but 
unlikely to change 
conclusion. 
 
Hanevik et al., Inadequate; Inadequate; No; patients 
had to pay 
No. Adequate follow-
up and reporting 
No reporting on 
adverse 
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2012 randomized blocks of 
10 envelopes with 3:2 
ratio for 
intervention/control 
picked randomly by 
patients. 
sealed 
envelopes 
used from 
blocks of 10 
with (potential 
of knowing 
allocation in 
advance by 
care provider 
and patient). 
partly for 
adjuvant 
treatment 
and no 
placebo was 
used. 
on participants. outcomes or side-
effects of 
medications. 
Moon et al., 2004 Unclear method of 
randomization. 
Unclear. Placebo was 
used so 
patients were 
blinded. 
Unclear. Adequate; all 
participants were 
reported on; 
however, it is 
unclear if patients 
participated more 
than once in the 
trial. 
No reporting on 
live birth rate or 
adverse 
outcomes or side-
effects. 
 
Moraloglu et al., 
2010 
Inadequate as 
randomization was by 
week day. 
Unclear. Patients 
were blinded 
as placebo 
infusion was 
used. 
Unclear. Adequate as all 
participants were 
reported on. 
No reporting on 
live birth rate or  
ectopic 
pregnancy. 
Exclusion of 
endometriosis 
and recurrent 
implantation 
failure 
patients may 
have biased 
results. 
Ng et al., 2014 Adequate method of 
randomization by 
computer-generated 
random sequence in 
Adequate by 
use of sealed 
enveloppes 
and research 
nurse not 
Patients 
were blinded 
as placebo 
infusion was 
Yes as codes of 
treatment and 
control groups 
were not 
revealed until 
Adequate as all 
participants were 
reported on. 
All clinically 
relevant 
outcomes were 
reported. 
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blocks of 10. involved in the 
study. 
used. after completion 
of study and 
analysis. 
 
Ohl et al., 2002 Adequate; 
Randomization by third 
party using randomly 
permuted  blocks of 
four with stratification. 
Adequate 
allocation 
concealment 
as allocation 
was by 
randomization 
service. 
Patients 
were blinded 
as placebo 
patches were 
used. 
Unclear  Inadequate as 
only less than 
50% of the target 
sample was 
recruited and 
reported on. 
All relevant 
outcomes are 
reported on. 
The study is 
underpowered 
as only less 
than 50% of 
target sample 
was recruited. 
Pinheiro et al., 
2003 
Adequate;  draw of lots 
using prepared 
randomization table. 
Unclear  Inadequate 
blinding as 
the control 
arm did not 
receive 
placebo. 
Unclear  Inadequate as 33 
patients (15%) 
were excluded 
from analysis after 
randomization as 
they stopped 
active treatment 
due to side 
effects. 
No reporting on 
the live birth rate, 
adverse 
outcomes (such 
as ectopic 
pregnancy 
rate/multiple 
pregnancy rate). 
Insufficient 
reporting on side-
effects of 
medications. 
Insufficient 
sample size 
and large 
drop out rate 
may have 
introduced 
bias. 
Rabiee et al,. 
2011 
Unclear method of 
randomization. 
Unclear. No; blinding 
of patients. 
No; blinding of 
assessors. 
Adequate 
reporting of all 
participants. 
Only biochemical 
pregnancy and 
side-effects 
reported  
No reporting on 
other clinically 
relevant 
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outcomes. 
Sohrabvand et 
al., 2014 
Unclear method of 
randomization. 
Unclear.  No; blinding 
of patients as 
no placebo 
was used. 
No clear 
evidence of 
blinding of 
assessors.  
Reporting on all 
included patients. 
No reporting on 
any clinically 
relevant outcome 
such as live birth 
rate or clinical 
pregnancy rate.  
Also no reporting 
on adverse 
outcomes such as 
spontaneous 
abortion rate or 
ectopic 
pregnancy rate; 
however, this was 
a pilot study. 
 
Sohrabvand et 
al., 2009 
Unclear method of 
randomization. 
Unclear  No; blinding 
of patients as 
no placebo 
used in the 
control arm; 
however, the 
study claims 
double 
blinding. 
No clear 
evidence of 
blinding of 
assessors. 
Adequate 
reporting on 
numbers enrolled 
in the study (n = 
66); however it is 
unclear why a 
number of the 
recruited (n = 356) 
patients were 
withdrawn. 
No reporting on 
any clinically 
relevant outcome 
such as live birth 
rate or clinical 
pregnancy rate;  
also no reporting 
on adverse 
outcomes such as 
spontaneous 
abortion rate or 
ectopic 
pregnancy rate. 
Number 
recruited at 
the time of the 
trial was 352 
patients but 
the number 
reported on in 
the trial is 66 
patients. 
 
The dose of 
indomethacin 
is very low 
and of 
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hyoscine is 
large. 
Tsirigottis et al., 
2000 
Unclear method of 
randomization. 
Unclear . 
 
Unclear if 
blinding was 
done. 
Unclear if 
blinding was 
done. 
Adequate 
reporting on all 
patients. 
No reporting on 
live birth and on 
side-effects or 
adverse 
outcomes. 
Small sample 
size with 
reduced 
power. 
Shaker et 
al.,1993 
Unclear method of 
randomization. 
Unclear.  Blinding of 
patients 
achieved.  
Blinding of 
assessors.   
Adequate 
reporting of all 
patients. 
No reporting on 
live birth, 
untoward 
outcomes as 
spontaneous 
abortion and 
ectopic 
pregnancy rates. 
 
Zargar et al., 
2013 
Unclear method of 
randomization 
Unclear. No; blinding 
of patients 
achieved. 
No blinding of 
assessors  as 
there was no 
placebo. 
 Adequate 
reporting on all 
patients 
participating in the 
trial. 
No reporting on 
live birth, 
untoward 
outcomes as 
spontaneous 
abortion and 
ectopic 
pregnancy and 
multiple 
pregnancy rates. 
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Table 3: GRADE summary of evidence table for the effect of uterine relaxants compared with placebo or no intervention in 
the peri-implantation period for patients having assisted reproduction treatment.  
Quality assessment 
Number of 
patients 
Effect 
Qualit
y 
Importa
nce 
Num
ber 
of 
studi
es 
Study 
design 
Risk 
of 
bias 
Inconsist
ency 
Indirect
ness 
Impreci
sion 
Other 
considera
tions 
Uterin
e 
relaxa
nts 
Placebo 
or no 
interven
tion 
Relat
ive 
(95% 
CI) 
Absol
ute 
(95% 
CI) 
Live birth (follow up: 10 months) 
4 Random
ized 
trials  
Serio
us
a 
 
Serious
b
 Not 
serious  
Serious
c
 None  234/6
87 
(34.1
%)  
214/630 
(34.0%)  
RR 
1.10 
(0.88 
to 
1.38)  
34 
more 
per 
1000 
(from 
41 
fewer 
to 
129  
more)  
⨁◯
◯◯ 
Very 
low
a,b,
c
 
Importa
nt  
Clinical pregnancy rate (follow up: 5 months) 
13  Random
ised 
trials  
Serio
us
a
 
Serious
b
 Not 
serious  
Serious
c
 None  564/1
465 
(38.5
%)  
442/129
5 
(34.1%)  
RR 
1.19 
(0.98 
to 
1.44)  
65 
more 
per 
1000 
(from 
7 
fewer 
to 
150 
more)  
⨁◯
◯◯ 
Very 
low
a,b,
c
 
 
 
Importa
nt  
Spontaneous abortion rate (follow up: 6 months) 
9  Random
ised 
trials  
Serio
us
a
 
Serious
b
 Not 
serious  
Serious
c
 None  79/49
9 
(15.8
%)  
86/421 
(20.4%)  
RR 
0.79 
(0.57 
to 
1.08)  
43 
fewer 
per 
1000 
(from 
16 
more 
to 88 
fewer
)  
⨁◯
◯◯ 
Very 
low
a,b,
c
 
 
 
Importa
nt  
Ectopic pregnancy (follow up: 12 weeks) 
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Quality assessment 
Number of 
patients 
Effect 
Qualit
y 
Importa
nce 
Num
ber 
of 
studi
es 
Study 
design 
Risk 
of 
bias 
Inconsist
ency 
Indirect
ness 
Impreci
sion 
Other 
considera
tions 
Uterin
e 
relaxa
nts 
Placebo 
or no 
interven
tion 
Relat
ive 
(95% 
CI) 
Absol
ute 
(95% 
CI) 
3  randomi
sed 
trials  
serio
us
a
 
serious
b
 not 
serious  
serious
c
 publicatio
n bias 
strongly 
suspected 
 4
 
11/27
1 
(4.1%)  
13/255 
(5.1%)  
RR 
0.80 
(0.36 
to 
1.75)  
10 
fewer 
per 
1000 
(from 
33 
fewer 
to 38 
more)  
⨁◯
◯◯ 
Very 
low
a,b,
c,d
 
 
 
Importa
nt  
Multiple pregnancy rate (follow up: 10 months) 
4  Random
ised 
trials  
Serio
us
a
 
Serious
b
 Not 
serious  
Serious
c
 Publicatio
n bias 
strongly 
suspected
d
 
86/31
9 
(27.0
%)  
85/270 
(31.5%)  
RR 
0.89 
(0.70 
to 
1.14)  
35 
fewer 
per 
1000 
(from 
44 
more 
to 94 
fewer
)  
⨁◯
◯◯ 
Very 
low
a,b,
c,d
 
Importa
nt  
a
Inadequate allocation concealment and blinding. 
b
significant clinical and statistical heterogenity. 
c
wide confidence interval crossing unity line. 
d
small number of studies included. 
 
MD, mean difference; RR,  relative risk . 
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